Staff Reports
President Donald Trump says the University of Miami handed the federal government a 1994 ibogaine Investigational New Drug (IND) application as a “historic gift” to speed up psychedelic research. The White House ties the claim to its push this spring to fast‑track treatments for serious mental illness, and to so‑called Right to Try access. It’s a big claim — and one that should come with a paper trail, not just a press line.
What the White House is claiming
The administration says Secretary Robert F. Kennedy Jr. received the University of Miami’s original ibogaine IND and that this will help the Food and Drug Administration move faster on research and access. That message rides on an executive order that directs federal agencies to prioritize psychedelic research, including ibogaine. For veterans and people suffering from addiction or PTSD, faster research sounds like a welcome promise. For journalists and taxpayers, fast talk needs fast evidence.
No public proof yet — where’s the receipt?
Here’s the catch: there’s no independent confirmation publicly available that the University of Miami actually transferred a 1994 IND to HHS or the FDA. No university press release, no agency acknowledgement and no uploaded transfer document has appeared in mainstream reporting or on institutional news pages. In other words, the White House has declared a “historic gift.” Reporters and watchdogs should ask to see the deed, the cover letter, or at least an agency intake log. If it exists, show it. If it doesn’t, don’t declare the store open yet.
Why an old IND file won’t magically rewrite rules
Even if someone did hand over a dusty 1994 file, that paper does not authorize doctors to start prescribing ibogaine tomorrow. The FDA’s IND process, DEA scheduling rules for controlled substances, and modern safety standards still apply. Ibogaine carries serious cardiac risks — QT prolongation and other issues that regulators rightly flagged in the past. An executive order can speed paperwork and funding, but it can’t erase the need for safety data, new trials, or proper regulatory review. Acting FDA Commissioner Kyle Diamantas will still have to follow the law, not a press release.
Demand transparency, but push for results
Conservatives who back medical innovation and veterans’ care should want both speed and scrutiny. If the administration is serious about helping veterans and others, it should publish the transfer documents or produce agency confirmation, fund rigorous trials, and clear the path for compassionate access where appropriate. Until the University of Miami or HHS shows the transfer paperwork, take the “historic gift” line with a healthy dose of skepticism — and keep pushing for real reforms that lower red tape without sacrificing patients’ safety. That’s the kind of tough, practical accountability Americans deserve.
